{"id":136930,"date":"2025-10-21T22:10:11","date_gmt":"2025-10-21T22:10:11","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/136930\/"},"modified":"2025-10-21T22:10:11","modified_gmt":"2025-10-21T22:10:11","slug":"nucleus-debuts-first-open-weight-ai-models-for-ivf-and-genetic-optimization-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/136930\/","title":{"rendered":"Nucleus Debuts First Open-Weight AI Models for IVF and Genetic Optimization"},"content":{"rendered":"<p><b>Classified in: <\/b><a href=\"https:\/\/www.lelezard.com\/en\/news\/science-technology\" rel=\"nofollow noopener\" target=\"_blank\">Science and technology<\/a><br \/><b>Subject: <\/b><a href=\"https:\/\/www.lelezard.com\/en\/subject1617-productservice.html\" rel=\"nofollow noopener\" target=\"_blank\">Product\/Service<\/a><\/p>\n<p>\nThe future of genetics must be open.<\/p>\n<p>\n<a rel=\"nofollow noopener\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmynucleus.com%2F&amp;esheet=54342329&amp;newsitemid=20251021897353&amp;lan=en-US&amp;anchor=Nucleus+Genomics&amp;index=1&amp;md5=4b4a5a9b962aedd9835b865c6269485d\" shape=\"rect\" target=\"_blank\">Nucleus Genomics<\/a> today launched Nucleus Labs, its new AI genomics research arm, and released Origin, a family of nine genetic optimization models that outperform all previous accuracy benchmarks in predicting health and longevity from an embryo&#8217;s DNA.<\/p>\n<p>\nTrained and validated on millions of people, Origin forecasts risks for age-related conditions like heart disease and cancer across diverse ancestries. With just five embryos, couples can expect a greater than 50% risk reduction in common diseases like Alzheimer&#8217;s, diabetes, and cancers.<\/p>\n<p>\nFor couples pursuing IVF, Origin offers a new way to plan for long-term health from the very start of life. Families and clinicians can now make more informed decisions about their future child&#8217;s wellbeing. It represents a fundamental change in how IVF is conducted and sets a new standard of scientific rigor in reproductive genetics.<\/p>\n<p>\n<b>Why it matters<\/b><\/p>\n<p>\nIn a first for the genomics industry, Nucleus is making its science completely transparent by open-weighting its models. In doing so, patients, researchers, clinicians, and companies can now access and build upon the research.<\/p>\n<p>\n&#8220;Too much of genetic optimization has been shrouded in secrecy,&#8221; said Kian Sadeghi, Founder and CEO of Nucleus Genomics. &#8220;We reject that. There&#8217;s enormous potential to improve lifelong health starting before birth ? and IVF is where that potential becomes real. Progress in genomics will now be faster and safer because of the launch of Origin.&#8221;<\/p>\n<p>\n<b>Driving transparency: A new standard in reproductive genetics<\/b><\/p>\n<p>\nAlongside the launch, Nucleus introduced the Genetic Optimization Hub ? a place for industry leaders and top researchers to show their work and improve genetic prediction. Nucleus has open-weighted its Origin family of models on the hub, and has invited other researchers and companies to do the same.<\/p>\n<p>\nNucleus wants to encourage open collaboration across IVF and medical research to ensure responsible and rapid innovation.<\/p>\n<p>\n<b>A turning point for genomics<\/b><\/p>\n<p>\nThe release of Origin is the first in a planned series of open-weight models. Nucleus says future models will expand optimization power even further, while setting new norms for transparency, safeguards, and responsible use.<\/p>\n<p>\n&#8220;Technology doesn&#8217;t exist in a vacuum,&#8221; added Sadeghi. &#8220;Its impact depends on how responsibly it&#8217;s used. By open-weighting Origin, we want to set a global standard for safe, equitable, and effective genetic optimization.&#8221;<\/p>\n<p>\n<b>About Nucleus Genomics<\/b><\/p>\n<p>\nNucleus Genomics builds clinical-grade genetics software focused on generational health. Its flagship product, <b>Nucleus IVF+<\/b>, integrates deep genomic insight into IVF ? enabling families to plan for health and longevity from the earliest stage. <a rel=\"nofollow noopener\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmynucleus.com%2F&amp;esheet=54342329&amp;newsitemid=20251021897353&amp;lan=en-US&amp;anchor=Learn+more&amp;index=2&amp;md5=299b3452913075de5df90196435d1cd4\" shape=\"rect\" target=\"_blank\">Learn more<\/a>.<\/p>\n<p>\nTo partner with Nucleus, please reach out to <a rel=\"nofollow noopener\" href=\"http:\/\/www.lelezard.com\/cdn-cgi\/l\/email-protection#92e2f3e0e6fcf7e0e1fafbe2e1d2ffebfce7f1fef7e7e1bcf1fdff\" shape=\"rect\" target=\"_blank\">[email\u00a0protected]<\/a>.<\/p>\n<p><\/p>\n<tr>\n<td>\n            These press releases may also interest you<\/p>\n<tr class=\"r_21983059\">\n<td class=\"col_date\">\n\t\t\t\tat 17:53<\/td>\n<td\/>\n\t\t<\/tr>\n<tr class=\"r_21983059\">\n<td\/>\n<td>\n<p>Videotron Ltd. (&#8220;Videotron&#8221;) today announced that it has issued a conditional notice of redemption for all of its outstanding 51\/8% Senior Notes due April 15, 2027 (the &#8220;Notes&#8221;), of which there is US$600 million aggregate principal amount outstanding&#8230;<\/p>\n<p><\/td>\n<\/tr>\n<tr class=\"r_21983049\">\n<td class=\"col_date\">\n\t\t\t\tat 17:40<\/td>\n<td\/>\n\t\t<\/tr>\n<tr class=\"r_21983049\">\n<td\/>\n<td>\n<p>Bone Solutions Inc., a Colleyville-based orthobiologics company specializing in magnesium-based technologies, announced that the U.S. Food and Drug Administration (FDA) has granted pediatric clearance for its Mg OSTEOCRETE and Mg OSTEOINJECT&#8230;<\/p>\n<p><\/td>\n<\/tr>\n<tr class=\"r_21983039\">\n<td class=\"col_date\">\n\t\t\t\tat 17:32<\/td>\n<td\/>\n\t\t<\/tr>\n<tr class=\"r_21983039\">\n<td\/>\n<td>\n<p>Digital Turbine, Inc. , a global mobile platform company,\u00a0announced it will host a conference call and webcast to discuss its fiscal 2026 second quarter financial results and operating progress on Tuesday, November 4th, at 4:30pm ET\/1:30pm PT. The&#8230;<\/p>\n<p><\/td>\n<\/tr>\n<tr class=\"r_21983036\">\n<td class=\"col_date\">\n\t\t\t\tat 17:31<\/td>\n<td\/>\n\t\t<\/tr>\n<tr class=\"r_21983036\">\n<td\/>\n<td>\n<p>DelveInsight&#8217;s Emphysema Market Insights report includes a comprehensive understanding of current treatment practices, emphysema emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented&#8230;<\/p>\n<p><\/td>\n<\/tr>\n<tr class=\"r_21983027\">\n<td class=\"col_date\">\n\t\t\t\tat 17:25<\/td>\n<td\/>\n\t\t<\/tr>\n<tr class=\"r_21983027\">\n<td\/>\n<td>\n<p>BIOQUAL, Inc. www.bioqual.com BIOQ(Pink Limited):<\/p>\n<p>Three Months Ended<\/p>\n<p>August 31,<\/p>\n<p>\u00a0<\/p>\n<p>2025<\/p>\n<p>\u00a0<\/p>\n<p>2024<\/p>\n<p>\u00a0<\/p>\n<p>Revenue<\/p>\n<p>$<\/p>\n<p>9,855,399<\/p>\n<p>\u00a0<\/p>\n<p>$<\/p>\n<p>11,770,482<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>Loss&#8230;<\/p>\n<p><\/td>\n<\/tr>\n<tr class=\"r_21983023\">\n<td class=\"col_date\">\n\t\t\t\tat 17:22<\/td>\n<td\/>\n\t\t<\/tr>\n<tr class=\"r_21983023\">\n<td\/>\n<td>\n<p>Videotron Ltd. (&#8220;Videotron&#8221;) today announced the pricing of its C$800 million aggregate principal amount of 3.950% Series 3 Senior Notes due October 15, 2032 (the &#8220;Notes&#8221;) (this offering, the &#8220;Offering&#8221;). The Notes will be sold at C$999.37 per&#8230;<\/p>\n<p><\/td>\n<\/tr>\n<tr>\n<td\/>\n<td\/>\n\t<\/tr>\n<p><\/td>\n<\/tr>\n<p>News published on 21 october 2025 at 10:05 and distributed by: <br \/> <a href=\"https:\/\/www.businesswire.com\" rel=\"nofollow noopener\" target=\"_blank\"><img decoding=\"async\" src=\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2025\/10\/businesswire.jpg\" border=\"0\"\/><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Classified in: Science and technologySubject: Product\/Service The future of genetics must be open. Nucleus Genomics today launched Nucleus&hellip;\n","protected":false},"author":2,"featured_media":126363,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[272],"tags":[79,207,10991,20717,18,440,72781,458,135,2741,8845,19,17,76588,76585,5,10692,133,9588,76584,132,4308,76583,5986,49817,11420,76586,38856,76587],"class_list":{"0":"post-136930","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-business","9":"tag-business-news","10":"tag-computer-news","11":"tag-current-events","12":"tag-eire","13":"tag-environment","14":"tag-environmental-news","15":"tag-genetics","16":"tag-health","17":"tag-health-news","18":"tag-holidays","19":"tag-ie","20":"tag-ireland","21":"tag-leisure-activities","22":"tag-leisure-activities-news","23":"tag-news","24":"tag-press-release","25":"tag-science","26":"tag-sciences","27":"tag-scientific-news","28":"tag-sports","29":"tag-sports-news","30":"tag-technological-news","31":"tag-tourism","32":"tag-tourism-news","33":"tag-transportation","34":"tag-transportation-news","35":"tag-travelling","36":"tag-travelling-news"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/136930","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=136930"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/136930\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/126363"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=136930"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=136930"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=136930"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}